A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL. The traditional ...

The evolving and increasingly complex regulatory landscape is creating new challenges for organizations, requiring more adaptive and responsive compliance and risk management approaches. Traditional ...